Release Date: March 03, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) reported its first quarter with product revenue, generating $7.7 million from Revv Forge in just five weeks post-launch. The FDA approved Revv Forge, a first-in-class mein inhibitor, for relapse refractory acute leukemia patients with KMT2A translocation, highlighting the company's strong execution and rapid market entry. Syndax Pharmaceuticals Inc (NASDAQ:SNDX) has a robust financial position with $692.4 million in cash equivalents and investments, expected to fund operations through profitability. The company is aggressively advancing its clinical development strategy for Revv Forge, with plans to file a supplemental new drug application to expand its indicated population. Syndax Pharmaceuticals Inc (NASDAQ:SNDX) has launched Nick Timbo in partnership with Insight, targeting chronic graft versus host disease, and is exploring further expansion opportunities.

Negative Points

Operating expenses for the fourth quarter were high at $104.0 million, with significant research and development and selling, general, and administrative expenses. The company is not providing revenue guidance for 2025, which may create uncertainty for investors. There is a reliance on a limited distribution model, which could impact inventory levels and distribution efficiency. The competitive landscape in oncology is evolving, and Syndax Pharmaceuticals Inc (NASDAQ:SNDX) faces challenges in maintaining its first-mover advantage. The company has not yet announced specific plans for regulatory submissions or partnerships for Revv Forge outside the US, which could delay international market expansion.

Q & A Highlights

Warning! GuruFocus has detected 4 Warning Signs with SNDX.

Q: How should we think about inventory levels throughout 2025, and any trends on repeat prescribers from some of the docs? A: Keith Goldan, CFO, mentioned that inventory levels are expected to remain at 2 to 3 weeks in the channel, similar to other specialty launches. Steve Kloster, Chief Commercial Officer, added that 33% of tier 1 and 2 accounts have ordered Revv Forge, and the majority of accounts have used it more than once, indicating positive repeat prescribing trends.

Q: For the 66% of tier 1 and 2 accounts that have not yet ordered, what do you expect for the cadence and extent of activation over the next 10 months? A: Steve Kloster, Chief Commercial Officer, stated that they are activating across all 2000 treatment centers, focusing on the top 200. They expect to gradually activate more accounts over the year, with a blend of tier 1 and tier 2 accounts.

Story Continues

Q: Are you seeing off-label use of Revv Forge, and how many patients are left on the expanded access program? A: Steve Kloster, Chief Commercial Officer, noted that off-label use is anecdotal, with some use in NPM1 and combination treatments. All eligible patients have transitioned from the expanded access program, which remains lightly used for off-label indications.

Q: What are your thoughts on the company's long-term vision and strategy for 2030? A: Michael Metzger, CEO, expressed an ambitious vision for the company to extend product reach, build a larger pipeline, and become a formidable specialty oncology company by 2030, with a focus on the US market and potential partnerships for ex-US expansion.

Q: Can you speak to your confidence in a broad recommendation by NCCN in the second quarter and payer discussions regarding reimbursement of patients with MPM1 mutations? A: Michael Metzger, CEO, expressed confidence in the data supporting approval and inclusion in NCCN guidelines. Steve Kloster, Chief Commercial Officer, added that payer coverage is growing, and claims are being paid across indications, indicating strong support from payers.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments